Pharnext : Presents a Business Update Webcast on May 20th, 2020
May 14, 2020 at 12:05 pm EDT
Share
Pharnext
Pharnext Presents a Business Update Webcast on May 20th, 2020
14-May-2020 / 18:00 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Pharnext Presents a Business Update Webcast on May 20th, 2020
PARIS, France,6:00 pm, May 14, 2020 (CET) - Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today confirmed the organization of a webcast to update on its current activities on May 20th, 2020 at 6:00 pm (CET).
During this webcast, David Horn Solomon, Chief Executive Officer, will provide a business update and overview of Pharnext.
Attendees can participate by weblink:https://channel.royalcast.com/webcast/pharnext/20200520_1/ or connect by phone using the following coordinates:
Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).